Value of FLT-PET Before and During Radiotherapy in Head and Neck Tumors
- Conditions
- Head and Neck Neoplasms
- Registration Number
- NCT00163176
- Lead Sponsor
- Radboud University Medical Center
- Brief Summary
Tumor cell proliferation and repopulation contribute to resistance to radiotherapy in head and neck cancer. Up to now, this characteristic is mostly assessed using biopsies acquired during inspection under general anaesthesia before treatment.
18F-FLT-PET (positron emission tomography) is a non-invasive imaging method showing areas of active proliferation. The aim of this study is to assess the value of the functional information gained by 18F-FLT-PET for radiotherapy planning and early tumor response assessment.
Prior to radiotherapy, a planning CT-scan and a 18F-FLT-PET scan are acquired. After approximately two weeks of radiotherapy a further PET scan is obtained.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 50
- Stage II - IV squamous cell carcinoma of the head-and-neck region, treated with radiotherapy or radiochemotherapy with curative intent.
- 18 years or older
- Informed consent
- Patients who have undergone surgery as primary tumor therapy.
- Patients treated with palliative intent.
- Pregnancy
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Correlation of 18F-FLT-PET-signal changes before and during therapy with treatment outcome (clinical response and local tumor control) 1 year
- Secondary Outcome Measures
Name Time Method Evaluation of the value of the functional information gained by 18F-FLT-PET regarding the definition of the planning target volume (PTV) for radiotherapy. 2 months Measurement of 18F-FLT-PET-signal changes during radiotherapy or radiochemotherapy. 2 months
Trial Locations
- Locations (1)
Radboud University Nijmegen, Department of Radiotherapy
🇳🇱Nijmegen, Gelderland, Netherlands